Strategic partnerships Ipsen’s ongoing and recent external collaborations with Quotient Sciences and Origami Therapeutics, focused on small molecule protein degraders, indicate a strong openness to co-development and contract research opportunities that can be leveraged for joint ventures, licensing discussions, or manufacturing partnerships.

North America leadership Appointment of Michelle Werner as executive VP and president of North America signals a prioritized market expansion plan in the region, presenting a doorway to engage on regional clinical development programs, market access strategies, and U.S. manufacturing or distribution partnerships.

Rare disease focus Ipsen collaborates on therapies for ultra-rare and inherited neurodegenerative disorders (FOP and other targets) and maintains a pipeline emphasis on protein degraders, creating sales opportunities in niche, high-need patient populations and with specialty distributors or CROs serving rare disease channels.

Serviceable scale With a global commercial footprint in over 30 countries and partnerships that expand manufacturing capabilities, there are multiple entry points for contract development and manufacturing organization (CDMO) services, including scale-up, regulatory support, and regional supply agreements.

R&D investment signal Ipsen’s commitment to investing over 20 percent of sales into R&D highlights a healthy pipeline and potential for early-access programs, joint research initiatives, and collaboration on breakthrough modalities that can drive long-term sales through strategic alliances and material supply deals.